• Tyligand Bioscience Receives IND Clearance from China NMPA for TSN084, a Multi-kinase Inhibitor to Address Tumor Resistance to Targeted Therapies

  2022-01-17

  Shanghai, Jan. 17th, 2022 - Tyligand Bioscience, a clinical-stage biotechnology company developing innovative small-molecule therapeutics against drug resistant cancers, today announced that its investigational new drug (IND) application of ...

  查看详情

• Tyligand Bioscience Receives IND Clearance from U.S. FDA for TSN084, a Multi-kinase Inhibitor to Address Tumor Resistance to Targeted Therapies

  2021-10-20

  Tyligand Bioscience, a clinical-stage biotechnology company developing innovative small-molecule therapeutics against drug resistant cancers, today announced that the U.S. Food and Drug Administration (FDA) has cleared an Investigational Ne ...

  查看详情

• Tyligand Bioscience Appoint Dr. Xiao Kai as Vice President

  2021-09-01

  On August 2, 2021, Tyligand Bioscience (Shanghai) Co., Ltd. announced the appointment of Dr. Xiao Kai as Vice President, responsible for Corporate and Business Development.

  查看详情

• Tyligand Bioscience appoints Dr. Cong Lei as Sr. VP of Clinical Development

  2021-08-01

  Tyligand Bioscience (Shanghai) Limited, a leading innovation-driven, clinical stage biotech, announced the appointment of Cong Lei, MD/PhD, as Senior Vice President of Clinical Development, where she will be responsible for formulating inn ...

  查看详情

• Tyligand Bioscience and Context Therapeutics Sign Strategic Development Agreement for Onapristone ER

  2020-03-13

  Tyligand Bioscience and Phildelphia based biotech Context Therapeutics announced the signing of collaboration agreements for the development, manufacturing, registration and future commercialization of onapristone extended release (ER).

  查看详情

• Tyligand Bioscience Aquired ONA-XR (Onapristone sustained relese) right of development and commercialization in Greater China

  2021-08-25

  Context and Tyligand entered into a license agreement whereby Tyligand was granted the exclusive right and sole responsibility for the development and commercialization of ONA-XR in China, Hong Kong and Macau (the “Territory”), and Contex ...

  查看详情